Fintel on MSN
B Riley Securities initiates coverage of Microbot Medical (MBOT) with buy recommendation
Fintel reports that on February 10, 2026, B. Riley Securities initiated coverage of Microbot Medical (NasdaqCM:MBOT) with a ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
Microbot Medical is transitioning from R&D to commercialization with its LIBERTY single-use robotic system for endovascular interventions. I assign MBOT a neutral rating with a 1-year price target of ...
Microbot Medical Inc. (MBOT) has been beaten down lately with too much selling pressure. While the stock has lost 28.2% over the past four weeks, there is light at the end of the tunnel as it is now ...
Microbot Medical Inc. (MBOT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results